Chin. J. Org. Chem. ›› 2015, Vol. 35 ›› Issue (5): 1022-1032.DOI: 10.6023/cjoc201410039 Previous Articles     Next Articles



张京玉a, 王清龙b, 侯学会b, 刘宏民c   

  1. a 河南中医学院药学院 郑州 450018;
    b 河南牧业经济学院质检系 郑州 450011;
    c 郑州大学药学院 郑州 450001
  • 收稿日期:2014-10-29 修回日期:2014-11-28 发布日期:2014-12-02
  • 通讯作者: 侯学会, 刘宏民;
  • 基金资助:


Rencent Advances in Cyclin-Dependent Kinase Inhibitors with Purine Scaffold

Zhang Jingyua, Wang Qinglongb, Hou Xuehuib, Liu Hongminc   

  1. a School of Pharmaceutical Science, Henan University of Taditional Chinese Medicine, Zhengzhou 450008;
    b Department of Quality Detection and Management, Henan University of Animal Husbandry and Economy, Zhengzhou 450011;
    c School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450001
  • Received:2014-10-29 Revised:2014-11-28 Published:2014-12-02
  • Supported by:

    Project supported by the Education Department of Henan Province Science and Technology Research Projects (No.14A150052), Scientific Research Plan of Zhenzhou (No.121PPTGG509-2).

Cell cycle is a basic characteristic of a cell that associates with its division and duplication. An entire cell cycle is regulated by a series of enzymes. The occurance of cell cycle disorder can lead to an excessive cell proliferation which may trigger cancer. However, the drugs that target cyclin-dependent kinases could spur the process of cancer cell apoptosis through interrupting the cell cycle. In this article, different kinds of cyclin-dependent kinases (CDKs), cyclins, the mechanism of cell cycle regulation and its relation with cancers are reviewed. The CDKs inhibitors with purine scaffold are introduced and their progresses in research and development are briefly discussed.

Key words: cell cycle, cyclin-dependent kinases, inhibitors, anticancer